Mountain Valley MD Holdings Inc (CSE:MVMD, OTCQB:MVMDF) has provided a sweeping update on how it is rapidly advancing its patented Quicksome oral drug formulation and Quicksol solubility formulation technologies through key initiatives.
The Toronto-based company is building a world-class organization centered around the implementation and licensing of its key technologies to global pharmaceutical, vaccine, and nutraceutical third parties.
READ: Mountain Valley MD Holdings completes licensing agreement with Red White and Bloom Brands
MVMD highlighted the following technologies, which are being developed with the objective to “improve the administration, efficacy and safety” of medicines, therapies, and nutraceuticals:
- Quicksome desiccation technology: It utilizes advanced liposomal technology and other stabilizing molecules to formulate active ingredients into more efficient product formats that are delivered sublingually, or that could be applied to applications to address cold chain distribution challenges.
- Quicksol technology: The technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.
- Porous Aluminum Nanostructure Adjuvant (PANA) technology: It has a high surface area for vaccine-antigen binding that the company believes may provide vaccine dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.
Significantly, MVMD’s technologies can have huge advantages during the transport and handling of vaccines and drugs to minimize excessive heat or cold exposure.
On July 31, 2020, MVMD first shared the results from a US Food and Drug Administration (FDA) Polio Vaccine Lab evaluation that confirmed the firm had successfully preserved Polio D Antigen in its proprietary Quicksome rapid dissolve sublingual technology.
In addition to its sublingual cold chain work, the company studied in the first half of 2021, whether it could apply a thin Quicksome desiccated liposome layer of Trivalent Inactivated Poliovirus Vaccine (tIPV) inside a vial for five days of exposure at 40 degrees Celsius and then reconstituted for injection at the point of administration. Based on the cold chain technology achievements, the company said it has “advanced additional characterization studies” with its proprietary Quicksome technology to “optimize application across different human and animal vaccines.”
MVMD said it is “finalizing agreements with third-party organizations” who specialize in vaccine research and is initiating studies of the company’s technologies across an expanded vaccine target list.
Additionally, MVMD is in discussions with a potential partner in South America to apply the company’s cold chain technology to targeted husbandry animal vaccines.
Exploring insulin space
The company is looking at the application of its technology to the “needleless administration of insulin” and is currently planning the execution of formulation experiments with the goal of optimizing the potential delivery of rapid-acting human insulin in a sublingual format.
In addition, the firm has initiated the selection process for a third party contract research organization (CRO) and is engaging experts in insulin science to support planning of necessary trials to validate the potential delivery of rapid-acting human insulin in a sublingual format.
MVMD expects to have information on formulation developments and to complete testing of formulations in a Type 1 diabetes model in the second half of 2022.
Tuberculosis work
The company has confirmed its ability to create a solubilized selamectin product using its patented Quicksol technology applied to the macrocyclic lactone drug class. Selamectin is characterized as “a highly insoluble molecule” and MVMD believes that there’s “significant potential” in treating mycobacterium-based infections in humans and animals with its solubilized format of the drug, Selactosol 1.5%.
MVMD has completed its initial assessment, necessary testing assays, and related preclinical protocols required to advance studies for its novel Selactosol 1.5% targeting mycobacterium-based infections. It plans to start pre-clinical studies with its Selactosol 1.5% solution in the latter half of 2022.
Oncology
MVMD said it is reviewing additional pre-clinical models to explore combinations of its patented Soluvec with existing chemotherapeutic and immunomodulatory treatments across solid tumor and hematological malignancies.
On April 5, 2022, the company was granted a Patent for ‘Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies’ for its solubilized ivermectin (Soluvec). The patent verifies the novel approach of MVMD’s technology to potential cancer types that the company is exploring.
MVMD also focused on the progress its technology has made in the aquaculture, husbandry animals, nutraceuticals, dose sparing adjuvant and coronavirus (COVID-19) verticals. Investors can read the comprehensive update here.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive